HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

Abstract
Evidence from rodent studies indicates that the beta-cell-derived neurohormone amylin exerts multiple effects on eating behavior, including reductions in meal size, intake of highly palatable foods, and stress-induced sucrose consumption. To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, "fast food" intake, and perceived control of eating in 88 obese subjects. After a 2-day placebo lead-in, subjects self-administered pramlintide (180 microg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications. Compared with placebo, pramlintide treatment elicited significant mean reductions from baseline in body weight on day 44 (-2.1 +/- 0.3 vs. +0.1 +/- 0.4%, P < 0.001), 24-h caloric intake (-990 +/- 94 vs. -243 +/- 126 kcal on day 3, P < 0.0001; -680 +/- 86 vs. -191 +/- 161 kcal on day 43, P < 0.01), portion sizes, and caloric intake at a "fast food challenge" (-385 +/- 61 vs. -109 +/- 88 kcal on day 44, P < 0.05). Pramlintide treatment also improved perceived control of eating, as demonstrated by a 45% placebo-corrected reduction in binge eating scores (P < 0.01). The results of this translational research study confirm in humans various preclinical effects of amylin agonism, demonstrating that pramlintide-mediated weight loss in obese subjects is accompanied by sustained reductions in 24-h food intake, portion sizes, fast food intake, and binge eating tendencies.
AuthorsSteven R Smith, John E Blundell, Colleen Burns, Cinzia Ellero, Brock E Schroeder, Nicole C Kesty, Kim S Chen, Amy E Halseth, Cameron W Lush, Christian Weyer
JournalAmerican journal of physiology. Endocrinology and metabolism (Am J Physiol Endocrinol Metab) Vol. 293 Issue 2 Pg. E620-7 (Aug 2007) ISSN: 0193-1849 [Print] United States
PMID17505051 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Amyloid
  • Anti-Obesity Agents
  • Islet Amyloid Polypeptide
  • Placebos
  • pramlintide
Topics
  • Adult
  • Amyloid (adverse effects, therapeutic use)
  • Anti-Obesity Agents (adverse effects, therapeutic use)
  • Appetite Regulation (drug effects)
  • Body Weight (drug effects)
  • Double-Blind Method
  • Energy Intake (drug effects)
  • Feeding Behavior (drug effects)
  • Female
  • Follow-Up Studies
  • Humans
  • Hunger (drug effects)
  • Islet Amyloid Polypeptide
  • Male
  • Middle Aged
  • Nausea (chemically induced)
  • Obesity (drug therapy)
  • Placebos
  • Satiation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: